A live podcast, roundtable discussion on radioligands was moderated by Brian Rini, MD of Vanderbilt-Ingram Cancer Center, and featured panelists Karen Autio, MD, and Michael Morris, MD, of Memorial Sloan Kettering Cancer Center, Gary T. Smith, MD, of Vanderbilt University Medical Center, and Tanya Dorff, MD, of City of Hope. In part one, the panelists review the latest developments in prostate cancer, with a focus on data presented at the 2024 European Society for Medical Oncology Congress, including SPLASH results, which explored the efficacy of Lutetium-177-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer. ...
Prostate Cancer
Advertisement
Latest News
18F rhPSMA-7.3 (rhPSMA) PET/MRI imaging is a potential "one-stop shop" for detecting biochemically recurrent prostate cancer.
The primary endpoint of rPFS was maintained in both cohorts.
Dr. Dorff shares highlights from Uromigos Live 2024 and talks about the role of ADT in prostate cancer treatment.
The CLARIFY trial leveraged PSMA PET imaging for personalized prostate cancer treatment and detecting distant metastases.
Advanced PSMA PET imaging improved surgical outcomes for patients with high-risk prostate cancer in the CLARIFY trial.
Early phase I data on 177Lu rhPSMA-10.1 has demonstrated an encouraging safety profile for the novel radioligand therapy.
Advertisement
Conference Coverage
During the final part of this panel, novel ADCs are explored and analyzed for use in different settings.
During the fourth segment of this panel, novel ADCs including HER3, Nectin-4, and BT8009 are analyzed.
In the third part of this panel, the use of HER2 ADCs in bladder cancer is explored.
In the second segment of this panel, the use of sacituzumab govitecan monotherapy and combinations is discussed.
In the first part of this panel, the use and impact of enfortumab vedotin in the bladder cancer landscape is considered.
Dr. Choueiri outlines the importance of experts putting their heads together to decide on how to approach gray areas.
Advertisement
Advertisement
Latest News
Part three of this prostate cancer roundtable covers prognostic factors such as Gleason scores and genomic assays.
Part two of this roundtable features a discussion on the role of bone scans compared to the newer PSMA PET scans.
The first part of this roundtable focuses on the impact of recent research on clinical practice.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.